InnoPharmax Inc. (TPEX:4172)

Taiwan · Delayed Price · Currency is TWD

11.80

-0.05 (-0.42%)

Jul 9, 2026, 2:59 PM CST

-26.71% (1Y)

Market Cap	1.27B -35.2%
Revenue (ttm)	68.99M +113.6%
Net Income	-184.40M
EPS	-1.71
Shares Out	107.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	250,352
Open	11.85
Previous Close	11.85
Day's Range	11.35 - 12.00
52-Week Range	10.10 - 23.75
Beta	0.02
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About InnoPharmax

InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company offers Imipenem and Cilastatin sodium solution under the Bestnem brand for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and joint infections; contrast agents, such as gadopentetate dimeglumine under the Gadomni brand; oncology agents comprising bendamustine under the Innomu... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1994

Employees 34

Stock Exchange Taipei Exchange

Ticker Symbol 4172

Full Company Profile

Financial Performance

In 2025, InnoPharmax's revenue was 68.99 million, an increase of 113.60% compared to the previous year's 32.30 million. Losses were -184.40 million, 85.7% more than in 2024.

Financial Statements